Implementation of cascade testing for the detection of familial hypercholesterolaemia

Current Opinion in Lipidology

Volumn 16, Issue 4, 2005, Pages 428-433

  Hadfield, S Gaye ^a,b   Humphries, Steve E ^a,b  

^a London IDEAS Genetics Knowledge Park   (United Kingdom)

^b ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

Cascade testing; DNA based tests; Familial hypercholesterolaemia; Family tracing

Indexed keywords

APOLIPOPROTEIN B; DNA; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; KEXIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN RECEPTOR; SERINE PROTEINASE; SUBTILIN;

BLOOD VESSEL FUNCTION; CASCADE TEST; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC ACCURACY; DIET; DNA DETERMINATION; DRUG EFFICACY; DRUG SAFETY; ETHICS; EXERCISE; FAMILIAL HYPERCHOLESTEROLEMIA; GENETIC RISK; GENETIC SCREENING; HUMAN; INSURANCE; LIFESTYLE; PRIORITY JOURNAL; PSYCHOLOGICAL ASPECT; REVIEW; SENSITIVITY AND SPECIFICITY; SMOKING CESSATION;

EID: 22544433489     PISSN: 09579672     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.mol.0000174152.76554.d6     Document Type: Review

References (25)

1. Austin MA, Hutter CM, Zimmern RL, Humphries SE. Genetic causes of monogenic heterozygous familial hypercholesterolemia: a HuGE prevalence review. Am J Epidemiol 2004; 160:407-420. Reviews the clinical diagnostic criteria used for familial hypercholesterolaemia and the genes involved. Familial hypercholesterolaemia mutations identified, and their prevalence in different populations, are cited. Includes a comprehensive reference list.
2. Neil HA, Hammond T, Huxley R, et al. Extent of underdiagnosis of familial hypercholesterolaemia in routine practice: prospective registry study. BMJ 2000; 321:148.
3. WHO - Human Genetics DoNDP. Familial hypercholesterolaemia: report of a second WHO Consultation. Geneva: WHO; 1999.
4. Bhatnagar D, Morgan J, Siddiq S, et al. Outcome of case finding among relatives of patients with known heterozygous familial hypercholesterolaemia. BMJ 2000; 321:1497-1500.
5. Umans-Eckenhausen MA, Defesche JC, Sijbrands EJ, et al. Review of first 5 years of screening for familial hypercholesterolaemia in the Netherlands. Lancet 2001; 357:165-168.
6. Marks D, Wonderling D, Thorogood M, et al. Cost effectiveness analysis of different approaches of screening for familial hypercholesterolaemia. BMJ 2002; 324:1303.
7. Wonderling D, Umans-Eckenhausen MA, Marks D, et al. Cost-effectiveness analysis of the genetic screening program for familial hypercholesterolemia in The Netherlands. Semin Vasc Med 2004; 4:97-104. Data from the nationwide screening programme in the Netherlands demonstrate the cost-effectiveness of genetic screening in terms of cost per life year gained. Life expectancy data for familial hypercholesterolaemia patients pre and post the statin era were taken from the Simon Broome register.
8. van Maarle MC, Stouthard ME, Marang-van de Mheen PJ, et al. How disturbing is it to be approached for a genetic cascade screening programme for familial hypercholesterolaemia? Psychological impact and screenees' views. Commun Genet 2001; 4:244-252.
9. Leren TP, Manshaus T, Skovholt U, et al. Application of molecular genetics for diagnosing familial hypercholesterolemia in Norway: results from a family-based screening program. Semin Vasc Med 2004; 4:75-85. The results of the Norwegian family tracing programme, 2000-2003, are reported. Genetic counsellors and general practitioners implement the programme in a low-density population. Fifty-three percent of affected, adult relatives were on lipid-lowering therapy before screening; this increased to 81% following diagnosis of familial hypercholesterolaemia.
10. Marks D, Thorogood M, Neil HA, Humphries SE. A review on the diagnosis, natural history, and treatment of familial hypercholesterolaemia. Atherosclerosis 2003; 168:1-14.
11. Scientific Steering Committee on behalf of the Simon Broome Register. Risk of fatal coronary heart disease in familial hypercholesterolaemia. BMJ 1991; 303:893-896.
12. Williams RR, Hunt SC, Schumacher MC, et al. Diagnosing heterozygous familial hypercholesterolemia using new practical criteria validated by molecular genetics. Am J Cardiol 1993; 72:171-176.
13. Damgaard D, Larsen ML, Nissen PH, et al. The relationship of molecular genetic to clinical diagnosis of familial hypercholesterolemia in a Danish population. Atherosclerosis 2005; 180:155-160. The ability of three sets of clinical criteria (Simon Broome, MEDPED and Dutch Lipid Clinic Network) to predict the molecular analysis of 408 familial hypercholesterolaemia patients was evaluated. At high specificities (definite familial hypercholesterolaemia) the tests have poor sensitivity and vice versa.
14. Pocovi M, Civeira F, Alonso R, Mata P. Familial hypercholesterolemia in Spain: case-finding program, clinical and genetic aspects. Semin Vasc Med 2004; 4:67-74.
15. Sozen M, Whittall R, Humphries SE. Mutation detection in patients with familial hypercholesterolaemia using heteroduplex and single strand conformation polymorphism analysis by capillary electrophoresis. Atheroscler Suppl 2004; 5:7-11.
16. Leren TP. Cascade genetic screening for familial hypercholesterolemia. Clin Genet 2004; 66:483-487. This mini review focuses on the organization of a cascade genetic screening programme for familial hypercholesterolaemia as well as cost-efficiency assessments, health benefits, possible adverse effects and the screening of children. The author concludes that cascade genetic screening for familial hypercholesterolaemia leads to health benefits and is cost-effective without causing psychological or social damage.
17. Wiegman A, Hutten BA, Groot E, et al. Efficacy and safety of statin therapy in children with familial hypercholesterolemia: a randomized controlled trial. JAMA 2004; 292:331-337. Two hundred and fourteen children with familial hypercholesterolaemia were assigned to a randomized, double-blind, placebo-controlled trial to determine the 2-year efficacy and safety of pravastatin. A significant regression in carotid intima-media thickness was observed in the treated group. No adverse effects were reported.
18. Greene O, Durrington P. Clinical management of children and young adults with heterozygous familial hypercholesterolaemia in the UK. J R Soc Med 2004; 97:226-229.
19. Newson AJ, Humphries SE. Cascade testing in familial hypercholesterolaemia: how should family members be contacted? Eur J Hum Genet 2005; 13:401-408. The alternative methods by which relatives can be contacted (via family members or healthcare workers) are examined for familial hypercholesterolaemia. Direct contact by healthcare workers is considered to be ethically justifiable for familial hypercholesterolaemia, and to improve the efficiency of the cascade process.
20. Andersen LK, Jensen HK, Juul S, Faergeman O. Patients' attitudes toward detection of heterozygous familial hypercholesterolemia. Arch Intern Med 1997; 157:553-560.
21. van Maarle MC, Stouthard ME, Bonsel GJ. Quality of life in a family based genetic cascade screening programme for familial hypercholesterolaemia: a longitudinal study among participants. J Med Genet 2003; 40:e3.
22. Marteau T, Senior V, Humphries SE, et al. Psychological impact of genetic testing for familial hypercholesterolemia within a previously aware population: a randomized controlled trial. Am J Med Genet A 2004; 128:285-293. The impact of genetic testing was assessed in 341 familial hypercholesterolaemia families who were randomly allocated to routine clinical testing or to routine clinical testing plus genetic testing. The main finding was that a molecular diagnosis does not reduce the perceived control over hypercholesterolaemia, but does affect perceptions of how control is best achieved.
23. Neil HA, Hammond T, Mant D, Humphries SE. Effect of statin treatment for familial hypercholesterolaemia on life assurance: results of consecutive surveys in 1990 and 2002. BMJ 2004; 328:500-501. The same 26 life assurance companies were asked to assess a fictional familial hypercholesterolaemia patient in 1990 (no treatment) and in 2002 (before and after statin treatment). The authors concluded that risk is now being assessed more realistically, that it is based on phenotype rather than genotype, and relatives of familial hypercholesterolaemia patients should not be deterred from testing because of concerns about life assurance.
24. Homsma SJ, Lansberg PJ, Kastelein JJ. Genetic screening of patients with familial hypercholesterolemia and insurability for life insurance policies and disability cover policies [in Dutch]. Ned Tijdschr Geneeskd 2004; 148:493-496.
25. Marks D, Thorogood M, Farrer JM, Humphries SE. Census of clinics providing specialist lipid services in the United Kingdom. J Public Health (Oxf) 2004; 26:353-354.